
    
      Participants will receive each treatment if the gastric cancer tissue sample reveals one of
      the following somatic aberrations:

        1. Anti-EGFR (GC-1118) in combination with weekly paclitaxel EGFR-amplification or strong
           (3+) EGFR immunostaining

        2. FGFR inhibitor (rogaratinib) in combination with weekly paclitaxel Gene amplifications,
           mRNA overexpression, oncogenic mutations, or gene fusions involving FGFR1, FGFR2, or
           FGFR3
    
  